Growth hormone reduces liver fat, inflammation in adults with NAFLD

ATLANTA — Adults with overweight or obesity and nonalcoholic fatty liver disease, or NAFLD, had a significant reduction in liver fat and inflammation with daily subcutaneous growth hormone administration, according to a speaker.“NAFLD is highly prevalent, poorly understood and still has no FDA-approved treatments,” Laura Dichtel, MD, MHS, assistant professor in the neuroendocrine unit of Massachusetts General Hospital and Harvard Medical School, said during a presentation at ENDO 2022. “We demonstrated that growth hormone administration improved NAFLD in adults withRead More

Related Articles